Pasithea Therapeutics Corp. (KTTA)
0.49
0.00 (0.00%)
USD |
NASDAQ |
Oct 22, 10:14
Pasithea Therapeutics Enterprise Value : -29.47M for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | -29.47M |
| October 20, 2026 | -32.07M |
| October 19, 2026 | -31.99M |
| October 16, 2026 | -31.73M |
| October 15, 2026 | -32.06M |
| October 14, 2026 | -32.09M |
| October 13, 2026 | -31.60M |
| October 12, 2026 | -30.81M |
| October 09, 2026 | -30.14M |
| October 08, 2026 | -31.03M |
| October 07, 2026 | -30.95M |
| October 06, 2026 | -30.83M |
| October 05, 2026 | -30.56M |
| October 02, 2026 | -29.86M |
| October 01, 2026 | -29.42M |
| September 30, 2026 | -29.29M |
| September 29, 2026 | -29.39M |
| September 28, 2026 | -29.73M |
| September 25, 2026 | -29.08M |
| September 24, 2026 | -28.60M |
| September 23, 2026 | -28.63M |
| September 22, 2026 | -28.59M |
| September 21, 2026 | -28.71M |
| September 18, 2026 | -28.27M |
| September 17, 2026 | -28.83M |
| Date | Value |
|---|---|
| September 16, 2026 | -29.39M |
| September 15, 2026 | -29.06M |
| September 14, 2026 | -28.72M |
| September 11, 2026 | -28.06M |
| September 10, 2026 | -27.72M |
| September 09, 2026 | -26.73M |
| September 08, 2026 | -25.75M |
| September 04, 2026 | -26.38M |
| September 03, 2026 | -26.37M |
| September 02, 2026 | -26.37M |
| September 01, 2026 | -26.95M |
| August 31, 2026 | -26.59M |
| August 28, 2026 | -27.05M |
| August 27, 2026 | -27.24M |
| August 26, 2026 | -26.72M |
| August 25, 2026 | -27.05M |
| August 24, 2026 | -28.89M |
| August 21, 2026 | -27.74M |
| August 20, 2026 | -30.06M |
| August 19, 2026 | -29.39M |
| August 18, 2026 | -29.14M |
| August 17, 2026 | -29.79M |
| August 14, 2026 | -29.71M |
| August 13, 2026 | -29.79M |
| August 12, 2026 | -29.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.593B |
| Alnylam Pharmaceuticals, Inc. | 29.78B |
| Anika Therapeutics, Inc. | 262.53M |
| Savara, Inc. | 816.59M |
| Vericel Corp. | 2.027B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.274M |
| Total Expenses (Quarterly) | 5.274M |
| EPS Diluted (Quarterly) | -0.1643 |
| Earnings Yield | -322.4% |
| Normalized Earnings Yield | -327.20 |